Nelson J, Chao, MD is a professor of Medicine at Duke Cancer Institute whose research focuses on clinical hematopoietic stem cell and cord blood transplantation.
Navigating Unmet Needs in SR/D cGvHD
Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Future Therapies in cGvHD
Dr. Zeiser and Dr. Chao review ongoing clinical trials in the management of cGvHD – specifically the use of axatilimab and abatacept in SR/D cGvHD.
Use of Subsequent Therapies in SR/D cGvHD
Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.
REACH3: Ruxolitinib in Steroid Refractory cGvHD
Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.
First line Treatment and Challenges in Chronic GvHD
Explore the primary treatment options for chronic Graft vs Host Disease (cGvHD) and delve into the challenges associated with prolonged steroid use, focusing on dosing strategies and adverse event management.
Navigating GvHD: Overview and Differences between Acute and Chronic GvHD
Two experts explore the essentials of Graft vs Host Disease (GvHD), understanding its symptoms, diagnosis, and distinguishing characteristics between acute and chronic forms.
Clinical Evolution of Treatment in Chronic Graft vs. Host Disease
Dr. Zeiser discusses the dynamic clinical evolution of Graft vs Host Disease (GvHD) in a concise overview, gaining insights into its progression and changing manifestations over time.
Closing Thoughts on the GVHD Treatment Landscape
Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.
Treatment Considerations for Chronic GVHD
A GVHD expert outlines the treatments available for patients with chronic GVHD and steroid-refractory chronic GVHD.
Overview of Acute and Chronic GVHD
Nelson J. Chao, MD, gives an overview of acute and chronic GVHD, and details the classical presentation and staging process.
Allogeneic Transplantation and GVHD Prophylaxis
An expert on graft-vs-host disease discusses allogeneic stem cell transplantation, and reviews transplant conditioning and GVHD prophylaxis regimens.
Patient Profile: A 35-Year-Old Woman with Chronic GVHD
Nelson J. Chao, MD, presents a patient profile of a 35-year-old woman diagnosed with chronic graft-vs-host disease, and provides his initial thoughts.
Chronic GVHD: Prognoses and Future Directions in Care
Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.
Scenario 2: Treatment-Induced Damage in Chronic GVHD
A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.
Scenario 2: Selecting Therapy for Steroid-Refractory GVHD
Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.
Scenario 2: Belumosudil and Axatilimab as Treatment Options in cGVHD
Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.
Scenario 2: Ibrutinib and Ruxolitinib as Treatment Options in cGVHD
A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.
Scenario 2: Identifying Chronic GVHD and Risk Status
Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.
Scenario 2: Challenges in Early Intervention for Chronic GVHD
Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.
Scenario 1: Optimizing Management of Acute GVHD
Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.
Scenario 1: Selecting Therapy for Acute Graft-Versus-Host Disease
A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.
Scenario 1: Acute GVHD Symptomology and Patient Education
Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.
Virtual Tumor Board®: An Overview on Graft-Versus-Host Disease and Prophylaxis
Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.
Home Care Delivery for Patients Undergoing HSCT During COVID-19
Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.
2 Commerce Drive Cranbury, NJ 08512